Can a new pill outperform chemotherapy for a Hard-to-Treat lung cancer mutation?
NCT ID NCT07754123
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assigned to receive either HS-10504 or standard platinum-based chemotherapy. The study aims to see if the new drug offers better control of the disease and potentially improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HS-10504 tablet
- What this could lead to
- If successful, HS-10504 could offer a new targeted treatment option for people with a specific lung cancer mutation that has stopped responding to current therapies.
- What could go wrong
- This is an early-stage trial, and the drug may not prove more effective or safer than standard chemotherapy. Side effects are possible, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.